The Coalition for Epidemic Preparedness Innovations has given up to US$19.3 million to an international partnership to promote the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate. The University of Sydney is a lead partner.
Bharat Biotech International Ltd (Bharat Biotech), India, ExcellGene SA, Switzerland, and the University of Sydney, Australia are working together. They are establishing preclinical and clinical proof of concept for a protein subunit vaccine that will provide broad protection against all known SARS-CoV-2 variants of concern and future and yet to emerge variants of the virus.
The researchers will get money from the Coalition for Epidemic Preparedness Innovations (CEPI) to pursue tasks such as immunogen design (to elicit a high immune response), preclinical studies, manufacturing process development, and a Phase 1 clinical trial.
Repeated waves of COVID-19 infection, according to CEPI CEO Dr. Richard Hatchett, warn us that we will be living with the virus for many years to come.